Nevertheless, the results suggest that FDG PET/MRI should be considered as a tool for oncological surveillance of patients who have undergone liver-transplantation for HCC, particularly in cases of allergy to contrast media, renal failure or persistently elevated AFP levels, and with no identification of metastatic/relapsing foci at standard-of-care imaging. This evidence concerns the gene AFP and Renal insufficiency.